ASML vs PFE: Which Is the Better Buy?
Side-by-side comparison of ASML Holding N.V. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
ASML Holding N.V. · Technology
$1,744.61
-0.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ASML |
PFE |
| Current Price |
$1,744.61 |
$27.64 |
| Fair Value Estimate |
$1,732.49 |
$30.94 |
| Upside to Fair Value |
-0.7%
|
+12.0%
|
| Market Cap |
$672.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
42.0x
|
17.4x
|
| Price / Sales |
19.0x
|
2.5x
|
| Price / FCF |
67.2x
|
14.3x
|
| Revenue Growth YoY |
+21.3%
|
+2.6%
|
| Gross Margin |
52.7%
|
71.3%
|
| Operating Margin |
35.4%
|
25.1%
|
| Return on Equity |
52.4%
|
4.9%
|
| Dividend Yield |
0.51% |
6.22% |
| FCF Yield |
1.49%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
ASML Holding N.V. is the Dutch semiconductor equipment maker that supplies lithography, metrology, and inspection systems, including the extreme ultraviolet (EUV) machines required to pattern the most advanced logic and memory chips, and it holds what current coverage describes as a near-monopoly on those EUV tools. The business quality is genuinely high: TTM gross margin of 52.7%, TTM operating …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
ASML |
PFE |
| Zone Low |
$1,299.37 |
$23.21 |
| Zone High |
$1,472.62 |
$26.30 |
| In Buy Zone? |
No
|
No
|